MPC based Artificial Pancreas: Strategies for individualization and meal compensation

This paper addresses the design of glucose regulators based on Model Predictive Control (MPC) to be used as part of Artificial Pancreas devices for type 1 diabetic patients. Two key issues are deeply investigated: individualization, needed to cope with intersubject variability, and meal compensation, interpreted as a disturbance rejection problem. The individualization is achieved either by tuning the cost function, based on few well known clinical parameters (MPC1) or through the use of an individual model obtained via system identification techniques and an optimal tuning of the cost function based on real-life experiments (MPC2). The in silico tests, performed on 4 different scenarios using a simulator equipped with 100 patients, show that the performances of MPC1 are very promising, supporting its current use in an in vivo multicenter trial on 47 patients that is being carried out within the European Research Project AP@home. At the same time, further improvements are achieved by MPC2, showing that there is scope for in vivo experimentation of control strategies employing individually estimated patient models.

[1]  Eyal Dassau,et al.  In Silico Preclinical Trials: Methodology and Engineering Guide to Closed-Loop Control in Type 1 Diabetes Mellitus , 2009, Journal of diabetes science and technology.

[2]  Roman Hovorka.  Management of diabetes using adaptive control , 2005 .

[3]  Giuseppe De Nicolao,et al.  Model predictive control of glucose concentration in type I diabetic patients: An in silico trial , 2009, Biomed. Signal Process. Control..

[4]  L. Magni,et al.  Evaluating the Efficacy of Closed-Loop Glucose Regulation via Control-Variability Grid Analysis , 2008, Journal of diabetes science and technology.

[5]  Ian Postlethwaite,et al.  Multivariable Feedback Control: Analysis and Design , 1996 .

[6]  William L Clarke,et al.  Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. , 2005, Diabetes technology & therapeutics.

[7]  A H Clemens,et al.  The development of Biostator, a Glucose Controlled Insulin Infusion System (GCIIS). , 1977, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[8]  L. Magni,et al.  Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results , 2010, Journal of diabetes science and technology.

[9]  R. Hovorka.  Continuous glucose monitoring and closed‐loop systems , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[10]  Janet M. Allen,et al.  Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial , 2010, The Lancet.

[11]  B. Bequette.  A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. , 2005, Diabetes technology & therapeutics.

[12]  R.S. Parker,et al.  A model-based algorithm for blood glucose control in Type I diabetic patients , 1999, IEEE Transactions on Biomedical Engineering.

[13]  Eyal Dassau,et al.  Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events , 2010, Journal of diabetes science and technology.

[14]  Marco Forgione,et al.  Run-to-Run Tuning of Model Predictive Control for Type 1 Diabetes Subjects: In Silico Trial , 2009, Journal of diabetes science and technology.

[15]  Efstratios N. Pistikopoulos,et al.  Model-based blood glucose control for type 1 diabetes via parametric programming , 2006, IEEE Transactions on Biomedical Engineering.

[16]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[17]  Giovanni Sparacino,et al.  Diabetes: Models, Signals, and Control , 2009 .

[18]  C. C. Palerm,et al.  Effect of input excitation on the quality of empirical dynamic models for type 1 diabetes , 2009 .

[19]  B. Zinman,et al.  Normalization of Glycemia in Diabetics During Meals with Insulin and Glucagon Delivery by the Artificial Pancreas , 1977, Diabetes.

[20]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[21]  Claudio Cobelli,et al.  Meal Simulation Model of the Glucose-Insulin System , 2007, IEEE Transactions on Biomedical Engineering.

[22]  Marc D. Breton,et al.  Modular Closed-Loop Control of Diabetes , 2012, IEEE Transactions on Biomedical Engineering.

[23]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[24]  L. Magni,et al.  Model Predictive Control of Type 1 Diabetes: An in Silico Trial , 2007, Journal of diabetes science and technology.

[25]  Robert G. Sutherlin,et al.  A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes , 2010, Science Translational Medicine.

[26]  W. Zingg,et al.  An Artificial Endocrine Pancreas , 1974, Diabetes.

[27]  R. Hovorka,et al.  Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. , 2004, Physiological measurement.